CollPlant Biotechnologies Ltd (CLGN) Latest Filing Signal

Latest Filing: 20-F  |  Filed Mar 26, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for CollPlant Biotechnologies Ltd?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 20-F, CollPlant Biotechnologies Ltd's filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
Pending
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does CollPlant Biotechnologies Ltd actually do?
Answer:
CollPlant Biotechnologies Ltd. is a regenerative and aesthetic medicine company leveraging its proprietary plant-based recombinant human collagen (rhCollagen) technology. The company develops products for medical aesthetics, tissue repair, and organ manufacturing, with its rhCollagen being bioidentical to human collagen and offering advantages over tissue-derived sources. CollPlant has a strategic development agreement with AbbVie for dermal and soft tissue filler products, and is also developing regenerative 3D-bioprinted breast implants and a photocurable dermal filler. Its rhCollagen-based bioink platform is utilized in 3D bioprinting for tissue and organ engineering. The company's operations are primarily based in Israel, with a focus on R&D and manufacturing of its unique collagen technology.
Question:
What are CollPlant Biotechnologies Ltd's revenue drivers?
Answer:
Revenues are primarily driven by sales of bioink and rhCollagen products, milestone payments from strategic partnerships (notably with AbbVie for dermal filler development), and potential future royalties on commercialized products.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required